Editor, OncLive®
Caroline Seymour is your initial point of contact for the OncLive® podcast, OncLive On Air™. She joined the company in 2018 as an assistant editor, with expertise in video production and print/digital publication. Email: cseymour@onclive.com
FDA Grants RMAT, Fast Track Designations to CB-010 in Relapsed/Refractory Non-Hodgkin Lymphoma
November 29th 2022The FDA has granted CB-010 a regenerative medicine advanced therapy designation for relapsed/refractory large B-cell lymphoma and a fast track designation for relapsed/refractory B-cell non-Hodgkin lymphoma.
Read More
NICE Recommends Nivolumab/Chemo for HER2- Advanced Stomach and Esophageal Cancer
November 29th 2022The United Kingdom’s National Institute for Health and Care Excellence has issued final guidance recommending the use of nivolumab plus chemotherapy as a treatment option for patients with HER2-negative advanced stomach and esophageal cancer.
Read More
DetermaIO Assay Helps Inform Benefit With Single-Agent Immunotherapy in Advanced NSCLC
November 22nd 2022The score of the 27-gene Determa immune-oncology assay demonstrated a correlation with overall survival and progression-free survival in patients with advanced non–small cell lung cancer treated with single-agent immunotherapy, regardless of performance status.
Read More
Ivonescimab Receives Breakthrough Therapy Designation for IO-Resistant NSCLC in China
November 16th 2022The Center for Drug Evaluation of the China National Medical Products Administration has granted a breakthrough therapy designation to ivonescimab plus docetaxel for patients with locally advanced or metastatic non–small cell lung cancer who failed to respond to a prior PD-(L)1 inhibitor plus platinum-based doublet chemotherapy.
Read More
FDA Approves First IHC Companion Diagnostic for Mirvetuximab Soravtansine in Ovarian Cancer
November 15th 2022The FDA has approved the VENTANA FOLR1 RxDx assay, the first immunohistochemistry companion diagnostic test to help identify patients with epithelial ovarian cancer who are eligible for treatment with mirvetuximab soravtansine-gynx.
Read More
Targeting the ‘New Kids on the Block’ in NSCLC: EGFR Exon 20 and MET Exon 14 Skipping Mutations
November 14th 2022Investigators are harnessing comprehensive molecular profiling to detect new targets, optimize existing treatment regimens, and develop novel therapies for patients with EGFR and MET exon 20–insertion positive non–small cell lung cancer.
Read More
European Commission Recommends Trastuzumab Deruxtecan Approval for Pretreated HER2+ Gastric Cancer
November 14th 2022The European Medicines Agency’s CHMP has recommended the approval of trastuzumab deruxtecan as monotherapy for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen.
Read More
Regorafenib Plus Ipilimumab and Nivolumab Shows Intriguing Activity in MSS mCRC
November 8th 2022Regorafenib plus ipilimumab and nivolumab led to encouraging survival and responses in approximately half of patients with microsatellite stable, non–liver metastatic colorectal cancer who progressed on prior chemotherapy.
Read More
Iomab-B Conditioning Elicits Durable CR in Relapsed/Refractory AML
October 31st 2022Reduced-intensity conditioning treatment plus Iomab-B prior to bone marrow transplant led to a durable and statistically significant 6-month complete remission rate vs conventional care in older patients with active, relapsed/refractory acute myeloid leukemia.
Read More
Camizestrant Improves PFS Vs Fulvestrant in Advanced ER+ Breast Cancer
October 26th 2022Camizestrant led to a statistically significant improvement in progression-free survival compared with fulvestrant in postmenopausal patients with estrogen receptor–positive, locally advanced, or metastatic breast cancer who were previously treated with endocrine therapy for advanced disease.
Read More
Sintilimab Plus Chemotherapy Improves PFS in Pretreated, EGFR-Mutant NSCLC
October 25th 2022Sintilimab plus pemetrexed and cisplatin significantly improved progression-free survival vs pemetrexed and cisplatin alone in patients with advanced, EGFR-mutant non–small cell lung cancer who progressed on prior EGFR TKI therapy.
Read More
Xevinapant Plus Chemoradiotherapy Improves OS in Locally Advanced Head and Neck Cancer
October 22nd 2022Xevinapant plus chemoradiotherapy more than halved the risk of death vs placebo plus chemoradiotherapy without increasing toxicity in patients with unresectable, locally advanced head and neck squamous cell carcinoma.
Read More
European Commission Approves Second-line Axi-cel for DLBCL/HGBL
October 18th 2022The European Commission has approved axicabtagene ciloleucel for the treatment of adult patients with diffuse large B-cell lymphoma or high-grade B-cell lymphoma who relapse within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy.
Read More
EMA Endorses Cemiplimab Approval in Advanced Cervical Cancer
October 14th 2022The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for cemiplimab monotherapy for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after platinum-based chemotherapy.
Read More
Long-Term Treatment With Ibrutinib Is Possible in Newly Diagnosed CLL/SLL
October 13th 2022Treatment with ibrutinib for at least 5 years showed favorable complete response rates and tolerability in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who were randomized to receive the BTK inhibitor in the phase 3 RESONATE-2 trial.
Read More
Ibrutinib Plus Venetoclax Improves Undetectable MRD Responses in Elderly, Unfit CLL
October 13th 2022Fixed-duration treatment with ibrutinib and venetoclax led to deeper and prolonged undetectable minimal residual disease responses vs chlorambucil and obinutuzumab in the frontline treatment of elderly or unfit patients with chronic lymphocytic leukemia, translating to fewer relapses in the first year following treatment cessation.
Read More
Avelumab and Axitinib Elicits Responses in Advanced Thymoma and Thymic Carcinoma
October 12th 2022The combination of avelumab and axitinib demonstrated promising response rates and progression-free survival and an expected safety profile in pretreated patients with advanced type B3 thymoma and thymic carcinoma, according to findings from an ongoing phase 2 study.
Read More
Frontline BR Plus ASCT and Maintenance Rituximab Demonstrates Activity in Transplant-Eligible MCL
October 10th 2022Bendamustine plus rituximab followed by autologous stem cell transplant and maintenance rituximab led to comparable outcomes defined by progression-free survival and objective response rate compared with R-CHOP/R-DHAP and ASCT as induction therapy in patients with mantle cell lymphoma.
Read More
Tivozanib Improves OS in Long-Term Responders in Relapsed/Refractory, Advanced RCC
October 10th 2022Tivozanib demonstrated an improvement in overall survival compared with sorafenib in pretreated patients with advanced clear cell renal cell carcinoma, particularly in those who remained progression-free at 1 year and beyond.
Read More